
Erasca Inc (ERAS) Stock Forecast & Price Target
Erasca Inc (ERAS) Analyst Ratings
Bulls say
Erasca Inc. is demonstrating strong potential for positive financial performance due to the promising results from its product pipeline, particularly Naporafenib, ERAS-007, and ERAS-601, which target critical nodes of the RAS/MAPK pathway. The company has reported significant efficacy in its combination studies, showing tumor growth inhibition of 77–83% as monotherapy, coupled with increased effectiveness when combined with treatments like cetuximab and anti-PD-1 checkpoint blockade. Additionally, recent presentations at the 2025 AACR Annual Meeting highlighted compelling preclinical data that further reinforce Erasca’s leadership in precision oncology, focusing on innovative therapies for RAS/MAPK pathway-driven cancers.
Bears say
Erasca Inc. faces a challenging financial outlook primarily due to the inherent risks associated with being a clinical-stage company reliant on the successful development and commercialization of its therapies, which are yet to generate revenue. The uncertainty surrounding the clinical trial outcomes for its lead candidates, Naporafenib and ERAS-007, coupled with significant research and development expenditures, places strain on the company's financial stability. Additionally, the competitive landscape within the oncology sector may hinder Erasca's ability to achieve milestones and secure necessary funding for future endeavors, impacting investor confidence and stock performance.
This aggregate rating is based on analysts' research of Erasca Inc and is not a guaranteed prediction by Public.com or investment advice.
Erasca Inc (ERAS) Analyst Forecast & Price Prediction
Start investing in Erasca Inc (ERAS)
Order type
Buy in
Order amount
Est. shares
0 shares